197 related articles for article (PubMed ID: 12490073)
1. Mice with a mutation in the thyroid hormone receptor beta gene spontaneously develop thyroid carcinoma: a mouse model of thyroid carcinogenesis.
Suzuki H; Willingham MC; Cheng SY
Thyroid; 2002 Nov; 12(11):963-9. PubMed ID: 12490073
[TBL] [Abstract][Full Text] [Related]
2. The pituitary tumor-transforming gene promotes angiogenesis in a mouse model of follicular thyroid cancer.
Kim CS; Ying H; Willingham MC; Cheng SY
Carcinogenesis; 2007 May; 28(5):932-9. PubMed ID: 17127711
[TBL] [Abstract][Full Text] [Related]
3. A tumor suppressor role for thyroid hormone beta receptor in a mouse model of thyroid carcinogenesis.
Kato Y; Ying H; Willingham MC; Cheng SY
Endocrinology; 2004 Oct; 145(10):4430-8. PubMed ID: 15231697
[TBL] [Abstract][Full Text] [Related]
4. Alterations in genomic profiles during tumor progression in a mouse model of follicular thyroid carcinoma.
Ying H; Suzuki H; Furumoto H; Walker R; Meltzer P; Willingham MC; Cheng SY
Carcinogenesis; 2003 Sep; 24(9):1467-79. PubMed ID: 12869418
[TBL] [Abstract][Full Text] [Related]
5. Mutant thyroid hormone receptor beta represses the expression and transcriptional activity of peroxisome proliferator-activated receptor gamma during thyroid carcinogenesis.
Ying H; Suzuki H; Zhao L; Willingham MC; Meltzer P; Cheng SY
Cancer Res; 2003 Sep; 63(17):5274-80. PubMed ID: 14500358
[TBL] [Abstract][Full Text] [Related]
6. Marked potentiation of the dominant negative action of a mutant thyroid hormone receptor beta in mice by the ablation of one wild-type beta allele.
Suzuki H; Zhang XY; Forrest D; Willingham MC; Cheng SY
Mol Endocrinol; 2003 May; 17(5):895-907. PubMed ID: 12576488
[TBL] [Abstract][Full Text] [Related]
7. Chromosomal aberrations in cell lines derived from thyroid tumors spontaneously developed in TRbetaPV/PV mice.
Zimonjic DB; Kato Y; Ying H; Popescu NC; Cheng SY
Cancer Genet Cytogenet; 2005 Sep; 161(2):104-9. PubMed ID: 16102579
[TBL] [Abstract][Full Text] [Related]
8. The steroid receptor coactivator-3 is a tumor promoter in a mouse model of thyroid cancer.
Ying H; Willingham MC; Cheng SY
Oncogene; 2008 Jan; 27(6):823-30. PubMed ID: 17653082
[TBL] [Abstract][Full Text] [Related]
9. AKT activation promotes metastasis in a mouse model of follicular thyroid carcinoma.
Kim CS; Vasko VV; Kato Y; Kruhlak M; Saji M; Cheng SY; Ringel MD
Endocrinology; 2005 Oct; 146(10):4456-63. PubMed ID: 16002527
[TBL] [Abstract][Full Text] [Related]
10. PTEN deficiency accelerates tumour progression in a mouse model of thyroid cancer.
Guigon CJ; Zhao L; Willingham MC; Cheng SY
Oncogene; 2009 Jan; 28(4):509-17. PubMed ID: 18997818
[TBL] [Abstract][Full Text] [Related]
11. Gelsolin: a novel thyroid hormone receptor-beta interacting protein that modulates tumor progression in a mouse model of follicular thyroid cancer.
Kim CS; Furuya F; Ying H; Kato Y; Hanover JA; Cheng SY
Endocrinology; 2007 Mar; 148(3):1306-12. PubMed ID: 17170101
[TBL] [Abstract][Full Text] [Related]
12. Thyroid hormone receptors are tumor suppressors in a mouse model of metastatic follicular thyroid carcinoma.
Zhu XG; Zhao L; Willingham MC; Cheng SY
Oncogene; 2010 Apr; 29(13):1909-19. PubMed ID: 20062085
[TBL] [Abstract][Full Text] [Related]
13. Growth activation alone is not sufficient to cause metastatic thyroid cancer in a mouse model of follicular thyroid carcinoma.
Lu C; Zhao L; Ying H; Willingham MC; Cheng SY
Endocrinology; 2010 Apr; 151(4):1929-39. PubMed ID: 20133453
[TBL] [Abstract][Full Text] [Related]
14. Synergistic signaling of KRAS and thyroid hormone receptor β mutants promotes undifferentiated thyroid cancer through MYC up-regulation.
Zhu X; Zhao L; Park JW; Willingham MC; Cheng SY
Neoplasia; 2014 Sep; 16(9):757-69. PubMed ID: 25246276
[TBL] [Abstract][Full Text] [Related]
15. Multi-tissue gene-expression analysis in a mouse model of thyroid hormone resistance.
Miller LD; McPhie P; Suzuki H; Kato Y; Liu ET; Cheng SY
Genome Biol; 2004; 5(5):R31. PubMed ID: 15128445
[TBL] [Abstract][Full Text] [Related]
16. Differential expression of thyroid hormone receptor isoforms dictates the dominant negative activity of mutant Beta receptor.
Zhang XY; Kaneshige M; Kamiya Y; Kaneshige K; McPhie P; Cheng SY
Mol Endocrinol; 2002 Sep; 16(9):2077-92. PubMed ID: 12198244
[TBL] [Abstract][Full Text] [Related]
17. PPARgamma insufficiency promotes follicular thyroid carcinogenesis via activation of the nuclear factor-kappaB signaling pathway.
Kato Y; Ying H; Zhao L; Furuya F; Araki O; Willingham MC; Cheng SY
Oncogene; 2006 May; 25(19):2736-47. PubMed ID: 16314832
[TBL] [Abstract][Full Text] [Related]
18. Regulation of beta-catenin by a novel nongenomic action of thyroid hormone beta receptor.
Guigon CJ; Zhao L; Lu C; Willingham MC; Cheng SY
Mol Cell Biol; 2008 Jul; 28(14):4598-608. PubMed ID: 18474620
[TBL] [Abstract][Full Text] [Related]
19. Novel non-genomic signaling of thyroid hormone receptors in thyroid carcinogenesis.
Guigon CJ; Cheng SY
Mol Cell Endocrinol; 2009 Sep; 308(1-2):63-9. PubMed ID: 19549593
[TBL] [Abstract][Full Text] [Related]
20. Activation of phosphatidylinositol 3-kinase signaling by a mutant thyroid hormone beta receptor.
Furuya F; Hanover JA; Cheng SY
Proc Natl Acad Sci U S A; 2006 Feb; 103(6):1780-5. PubMed ID: 16446424
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
